Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-04-10
2008-09-30
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C424S133100, C424S141100, C424S143100, C435S069600, C435S070210
Reexamination Certificate
active
07429644
ABSTRACT:
Humanized antibodies to LT-β-R and methods of use thereof are provided.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0104971 (2006-05-01), Garber et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0222644 (2006-10-01), Garber et al.
patent: 2006/0280722 (2006-12-01), Browning et al.
patent: 0519596 (1992-12-01), None
patent: 0519596 (2005-02-01), None
patent: WO 92/00329 (1992-01-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 94/13808 (1994-06-01), None
patent: WO 96/22788 (1996-08-01), None
patent: WO-91/09967 (1997-07-01), None
patent: WO 99/38525 (1999-08-01), None
patent: WO-99/58679 (1999-11-01), None
Kreitman et al. Advanced Drug Delivery Reviews, 31:53-88, 1998.
William E. Paul. Fundamental Immunology, 3rd ed., p. 242, 1993.
Paul, W. E., Fundamental Immunology, pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, 1982.
Browning et al. “Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.”J Immunol.Jan. 1, 1995;154(1):33-46.
Browning et al. “Signaling through the lymphotoxin β receptor induces the death of some adenocarcinoma tumor lines.”J Exp Med.Mar. 1, 1996;183(3):867-78.
Couto et al. “Humanization of KC4G3, an anti-human carcinoma antibody.”Hybridoma.Jun. 1994;13(3):215-9.
Foote et al. “Antibody framework residues affecting the conformation of the hypervariable loops.”J Mol Biol.Mar. 20, 1992;224(2):487-99.
Kolbinger et al. “Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.”Protein Eng.Nov. 1993;6(8):971-80.
He, Xiaozhong et al. “General Introduction to Modern Biological Technique”Publishing House of Beijing Normal University, 1stEdition, pp. 254-256 (1.8.3 & 1.8.4).
Riechmann, Lutz et al., “Reshaping human antibodies for therapy,”Nature,vol. 332:323-327 (1998).
Tempest, Philip R. et al., “Reshaping a Human Monoclonal Antibody To Inhibit Human Respiratory Syncytial Virus Infection In Vivo,”Biotechnology,vol. 9:266-271 (1991).
Alderson, Mark R. et al., “Regulation of apoptosis and T cell activation by Fas-specific mAb,”International Immunology, vol. 6(11):1799-1806 (1994).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry,vol. 267(4):2542-2547 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med.,vol. 177:1439-1450 (1993).
Bernstein, David L. et al., “Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development,”Antiviral Research,vol. 20:45-55 (1993).
Browning, Jeffrey L. et al., “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Immunology,vol. 147(4):1230-1237 (1991).
Browning, Jeffrey L. et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,”Cell,vol. 72:847-856 (1993).
Browning, Jeffrey L. et al., “Signaling through the Lymphotoxin-β Receptor in Conjunction with Interferon-γ Induces the Death of a Human Tumor Line,”The 9th International Congress of Immunology,pp. 772, No. 4582 (1995).
Browning, Jeffrey L. et al., “Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines,”The Journal of Immunology,vol. 143(6):1859-1867 (1989).
Crowe, Paul D. et al., “A Lymphotoxin-β-Specific Receptor,”Science,vol. 264:707-710 (1994).
Crowe, Paul D. et al., “Production of lymphotoxin (LTα) and a soluble dimeric form of its receptor using the baculovirus expression system,”Journal of Immunological Methods,vol. 168:79-89 (1994).
Dhein, Jens et al., “Induction of Apoptosis by Monoclonal Antibody Anti-Apo-1 Class Switch Variants is Dependent on Cross-Linking of Apo-1 Cell Surface Antigens,”The Journal of Immunology,vol. 149(10):3166-3173 (1992).
Dighe, Anand S. et al., “Enhanced In Vivo Growth and Resistance to Rejection of Tumor Cells Expressing Dominant Negative IFNγ Receptors,”Immunity,vol. 1:447-456 (1994).
Düzgünes, Nejat et al., “Liposome Targeting to HIV-Infected Cells Via Recombinant Soluble CD4 and CD4-IgG (Immunoadhesin),”Journal of Cellular Biochemistry,vol. 16E:77 (1992).
Eppstsein, Deborah A. et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,”Proc. Natl. Acad. Sci. USA,vol. 82:3688-3692 (1985).
Fukushima, Keiko et al., “N-Linked Sugar Chain Structure of Recombinant Human Lymphotoxin Produced by CHO Cells: The Functional Role of Carbohydrate as to Its Lectin-like Character and Clearance Velocity,”Archives of Biochemistry and Biophysics,vol. 304(1):144-153 (1993).
Havell, Edward A. et al., “The Antitumor Function of Tumor Necrosis Factor (TNF), I. Therapeutic Action of TNF against an Established Murine Sarcoma Is Indirect, Immunologically Dependent, and Limited by Severe Toxicity,”J. Exp. Med.,vol. 167:1067-1085 (1988).
Hwang, Karl J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study,”Proc. Natl. Acad. Sci. USA,vol. 77(7):4030-4034 (1980).
Johne, Berit et al., “Epitope mapping and binding kinetics of monoclonal antibodies studied by real time biospecific interaction analysis using surface plasmon resonance,”Journal of Immunological Methods,vol. 160:191-198 (1993).
Jurásková, Vera et al., “Interferon inducer, polyriboguanylic-polyribocytidylic acid, inhibits experimental hepatic metastases in mice,”European Journal of Pharmacology,vol. 221:107-111 (1992).
Kawabe, Tsutomu et al., “The Immune Responses in CD40-Deficient Mice: Impaired Immunoglobulin Class Switching and Germinal Center Formation,”Immunity,vol. 1:167-178 (1994).
Kolanus, Waldemar et al., “T Cell Activation by Clustered Tyrosine Kinases,”Cell,vol. 74:171-183 (1993).
Kopp, William C. et al., “Immunomodulatory Effects of Interferon-γ in Patients with Metastatic Malignant Melanoma,”J. of Immunother.,vol. 13:181-190 (1993).
Lane, Peter et al., “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes,”Eur. J. Immunol.,vol. 22:2573-2578 (1992).
Langer, Robert et al., “Biocompatibility of polymeric delivery systems for macromolecules,”Journal of Biomedical Meterials Research,vol. 15:267-277 (1981).
Langer, Robert et al., “Controlled release of macromolecules,”Chemtech.,vol. 12:98-105 (1982).
Ling, Leona E. et al., “Human Type I Interferon Receptor, IFNAR, Is a Heavily Glycosylated 120-130 kD Membrane Protein,”Journal of Interferon and Cytokine Research,vol. 15:55-61 (1995).
Loetscher, Hansruedi et al., “Recombinant 55-kDa Tumor N
Garber Ellen
Lyne Paul
Saldanha Jose William
Biogen Idec MA Inc.
Blanchard David J.
Cowles Cristin Howley
Lahive and Cockfield, LLP
Mandragouras Esq. Amy E.
LandOfFree
Humanized anti-LT-β-R antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-LT-β-R antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-LT-β-R antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974760